| Extension of Time to Hold Annual General Meeting | Nov 19, 2026 | Meeting notice | ASX |
|---|
| Bell Potter Healthcare Conference Presentation | Nov 16, 2026 | Operations update | ASX |
|---|
| Optiscan Strengthens Board with Appointment of Russell Low | Nov 4, 2026 | Management or board change | ASX |
|---|
| Notification of cessation of securities - OIL | Nov 3, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Optiscan Lodges U.S. FDA 510(k) Submission for InVue | Oct 4, 2026 | Operations update | ASX |
|---|
| Optiscan Lodges U.S. FDA 510(k) Submission for InForm | Oct 1, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice | Sep 15, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - OIL | Sep 15, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - OIL | Sep 15, 2026 | Financing | ASX |
|---|
| Significant Milestone Reached in ACL Digital Pathology Study | Sep 9, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice | Sep 9, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - OIL | Sep 9, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - OIL | Sep 8, 2026 | Financing | ASX |
|---|
| Change of Director's Interest Notice | Sep 8, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice | Sep 8, 2026 | Ownership change notice | ASX |
|---|
| Optiscan Initiates Head and Neck Cancer Study in the US | Aug 31, 2026 | Operations update | ASX |
|---|
| Preliminary Final Report | Aug 24, 2026 | Results | ASX |
|---|
| Appendix 4G & Corporate Governance Statement | Aug 24, 2026 | Other filings | ASX |
|---|
| 2026 Annual Report | Aug 24, 2026 | Annual report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 30, 2026 | Quarterly report | ASX |
|---|
| Optiscan Signs New Research Agreement for Breast Study | Jul 21, 2026 | Operations update | ASX |
|---|
| Head and Neck Study Progressing Ahead of Schedule | Jul 20, 2026 | Operations update | ASX |
|---|
| Optiscan Launches InSpecta Device for Veterinary Medicine | Jul 6, 2026 | Operations update | ASX |
|---|
| Halfway Mark Reached in Optiscan Breast Cancer Study | Jun 3, 2026 | Operations update | ASX |
|---|
| Second Anniversary of Optiscan and Mayo Clinic Agreement | May 31, 2026 | Operations update | ASX |
|---|
| Optiscan Receives $1.69m R&D Tax Refund | May 19, 2026 | Results | ASX |
|---|
| Optiscan Submits InSpecta FDA Dossier | Mar 30, 2026 | Operations update | ASX |
|---|
| Appendix 4D | Feb 24, 2026 | Interim report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Optiscan Initiates Head & Neck Cancer Imaging Study | Dec 2, 2025 | Operations update | ASX |
|---|
| Optiscan Partners with ACL to Advance Digital Pathology | Nov 10, 2025 | Operations update | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Aug 29, 2025 | Results | ASX |
|---|
| Entitlement Issue Prospectus | Aug 27, 2025 | Financing | ASX |
|---|
| Optiscan Launches Entitlement Offer to Raise $17.75m | Aug 27, 2025 | Financing | ASX |
|---|
| Optiscan Initiates Breast Cancer Study in Melbourne | Jun 30, 2025 | Other filings | ASX |
|---|
| Optiscan Signs Agreement with Long Grove Pharmaceuticals | Jun 22, 2025 | Acquisition or disposal | ASX |
|---|
| Optiscan Reveals InSpecta Device for Veterinary Medicine | Jun 9, 2025 | Operations update | ASX |
|---|
| Optiscan Completes Cloud-based Telepathology Software MVP | May 26, 2025 | Other filings | ASX |
|---|
| Robotic Surgery Collaboration with Mayo Clinic Progresses | May 12, 2025 | Operations update | ASX |
|---|
| Optiscan Reveals InForm Imaging Device for Pathology | Feb 18, 2025 | Operations update | ASX |
|---|
| Optiscan Initiates GI Study in Germany with First Prototype | Feb 2, 2025 | Operations update | ASX |
|---|
| OIL December 2024 Quarterly Report and Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| Optiscan receives $1.775m R&D Tax Refund | Jan 30, 2025 | Results | ASX |
|---|
| OIL Managing Director's Presentation & Chair's Address | Nov 21, 2024 | Other filings | ASX |
|---|
| Optiscan Signs Research Agreement with Minnesota Vet College | Nov 18, 2024 | Other filings | ASX |
|---|
| Optiscan Signs Agreement with Monash to Progress GI Scope | Nov 3, 2024 | Operations update | ASX |
|---|
| OIL September 2024 Quarterly Report and Appendix 4C | Oct 31, 2024 | Quarterly report | ASX |
|---|
| Appendix 4E Preliminary Final Report | Aug 30, 2024 | Results | ASX |
|---|
| Optiscan Signs MOU with University of Minnesota | Aug 18, 2024 | Operations update | ASX |
|---|
| OIL June 2024 Quarterly Report and Appendix 4C | Jul 31, 2024 | Quarterly report | ASX |
|---|
| Optiscan Delivers Major Milestone in Telepathology Platform | Jul 28, 2024 | Operations update | ASX |
|---|
| Optiscan Receives Ethical Clearance for Breast Cancer Study | Jul 14, 2024 | Operations update | ASX |
|---|
| Optiscan 2024 Roadshow Presentation | Jun 30, 2024 | Other filings | ASX |
|---|
| Optiscan Reveals InVue Imaging Device for Precision Surgery | Jun 3, 2024 | Other filings | ASX |
|---|
| Optiscan Webinar Investor Presentation | May 16, 2024 | Other filings | ASX |
|---|
| Optiscan Signs Know-How Agreement with Mayo Clinic | May 12, 2024 | Operations update | ASX |
|---|
| OIL March 2024 Quarterly Report and Appendix 4C | Apr 30, 2024 | Quarterly report | ASX |
|---|
| Optiscan appoints US Clinical & Regulatory Heads | Apr 2, 2024 | Management or board change | ASX |
|---|
| OIL Appendix 4D and 31 December 2023 Half-year report | Feb 22, 2024 | Interim report | ASX |
|---|
| Optiscan receives $3 million CRC-P Industry Grant | Feb 13, 2024 | Operations update | ASX |
|---|
| OIL December 2023 Quarterly Report and Appendix 4C | Jan 30, 2024 | Quarterly report | ASX |
|---|
| Response to ASX Price Query | Nov 14, 2023 | Explanation request | ASX |
|---|
| OIL September 2023 Quarterly Report and Appendix 4C | Oct 31, 2023 | Quarterly report | ASX |
|---|
| Optiscan Correlates with Histology in Breast Study | Sep 19, 2023 | Operations update | ASX |
|---|
| OIL Appendix 4E and June 2023 Annual Report | Aug 30, 2023 | Annual report | ASX |
|---|
| Optiscan Achieves Telepathology Milestone | Aug 14, 2023 | Other filings | ASX |
|---|
| OIL June 2023 Quarterly Report and Appendix 4C | Jul 28, 2023 | Quarterly report | ASX |
|---|
| Entitlement Offer Results and Shortfall Announcement | Jul 12, 2023 | Financing | ASX |
|---|
| Optiscan Entitlement Issue Prospectus | May 30, 2023 | Financing | ASX |
|---|
| Optiscan Launches Entitlement Offer to Raise $16.7M | May 30, 2023 | Financing | ASX |
|---|
| Trading Halt | May 25, 2023 | Trading halt or suspension | ASX |
|---|
| OIL March 2023 Quarterly Report and Appendix 4C | Apr 28, 2023 | Quarterly report | ASX |
|---|
| Optiscan Platform Highly Accurate for Oral Cancer Diagnosis | Mar 13, 2023 | Other filings | ASX |
|---|
| Optiscan Intends to pursue De Novo Pathway for InVivage | Mar 2, 2023 | Other filings | ASX |
|---|
| OIL Appendix 4D and 31 December 2022 Half-year report | Feb 27, 2023 | Interim report | ASX |
|---|
| Optiscan partners with Prolucid to develop AI Algorithms | Jan 29, 2023 | Other filings | ASX |
|---|
| OIL December 2022 Quarterly Report and Appendix 4C | Jan 27, 2023 | Quarterly report | ASX |
|---|
| Optiscan Managing Director 2022 AGM Presentation | Nov 24, 2022 | Other filings | ASX |
|---|
| OIL September 2022 Quarterly Report and Appendix 4C | Oct 31, 2022 | Quarterly report | ASX |
|---|
| Optiscan Imaging Acquires Intellectual Property | Oct 24, 2022 | Acquisition or disposal | ASX |
|---|
| Appendix 4E and 2022 Annual Report | Aug 31, 2022 | Annual report | ASX |
|---|
| Optiscan Submits FDA 510(k) Application for InVivage Device | Aug 21, 2022 | Other filings | ASX |
|---|
| OIL June 2022 Quarterly Report and Appendix 4C | Jul 29, 2022 | Quarterly report | ASX |
|---|
| Strategic Distribution Partnership - Additional Information | Jun 28, 2022 | Other filings | ASX |
|---|
| Optiscan announces Strategic Distribution Partner for China | Jun 26, 2022 | Other filings | ASX |
|---|
| OIL March 2022 Quarterly Report and Appendix 4C | Apr 29, 2022 | Quarterly report | ASX |
|---|
| Appendix 4D and 31 December 2021 Half-year report | Feb 24, 2022 | Interim report | ASX |
|---|
| OIL December 2021 Quarterly Report and Appendix 4C | Jan 31, 2022 | Quarterly report | ASX |
|---|
| 2021 AGM Chairmans Address and MD Presentation | Jan 20, 2022 | Other filings | ASX |
|---|
| Change of Managing Director | Dec 12, 2021 | Other filings | ASX |
|---|
| Completion of imaging for Melbourne Breast cancer trial | Nov 11, 2021 | Other filings | ASX |
|---|
| OIL September 2021 Quarterly Report and Appendix 4C | Oct 26, 2021 | Quarterly report | ASX |
|---|
| Receipt of R&D Tax Incentive Rebate | Oct 25, 2021 | Other filings | ASX |
|---|
| OIL FY21 Annual Results Presentation | Aug 30, 2021 | Other filings | ASX |
|---|
| Appendix 4E and 2021 Annual Report | Aug 30, 2021 | Annual report | ASX |
|---|
| OIL June 2021 Quarterly Report and Appendix 4C | Jul 29, 2021 | Quarterly report | ASX |
|---|
| Update on seeking United States FDA approval & market entry | May 31, 2021 | Other filings | ASX |
|---|
| OIL March 2021 Quarterly Report and Appendix 4C | Apr 28, 2021 | Quarterly report | ASX |
|---|
| Appointment of New Non-executive Chair | Apr 18, 2021 | Management or board change | ASX |
|---|
| Appendix 4D and Financial Statements - 31 December 2020 | Feb 25, 2021 | Interim report | ASX |
|---|
| OIL breast cancer study to commence next stage - revised | Feb 8, 2021 | Other filings | ASX |
|---|
| Optiscan breast cancer study to commence next stage | Feb 8, 2021 | Other filings | ASX |
|---|
| OIL December 2020 Quarterly Report and Appendix 4C | Jan 28, 2021 | Quarterly report | ASX |
|---|
| Carl Zeiss Meditec AG Product Orders | Jan 12, 2021 | Other filings | ASX |
|---|
| Appointment of Taiwan Distributor | Dec 15, 2020 | Other filings | ASX |
|---|
| OIL 2020 AGM Presentation | Nov 26, 2020 | Other filings | ASX |
|---|
| TGA Approval for CONVIVO and Sterile Sheath In Australia | Nov 9, 2020 | Other filings | ASX |
|---|
| OIL September 2020 Quarterly Report and Appendix 4C | Oct 29, 2020 | Quarterly report | ASX |
|---|
| US FDA Regulatory Approval update | Oct 8, 2020 | Other filings | ASX |
|---|
| OptiScan Capital Raising | Sep 24, 2020 | Financing | ASX |
|---|
| Optiscan Capital Raising | Sep 21, 2020 | Financing | ASX |
|---|
| Pause in Trading | Sep 21, 2020 | Trading halt or suspension | ASX |
|---|
| Appendix 4E and 2020 Annual Report | Aug 31, 2020 | Annual report | ASX |
|---|
| New North American & Expanded Asia Pacific Distribution | Aug 28, 2020 | Other filings | ASX |
|---|
| OIL June 2020 Quarterly Report and Appendix 4C | Jul 31, 2020 | Quarterly report | ASX |
|---|
| 2 X China Tender Success for FIVE2 (ViewnVivo) | Jul 27, 2020 | Other filings | ASX |
|---|
| Government grant to support Melbourne Dental School Trial | Jul 19, 2020 | Other filings | ASX |
|---|
| Achievement of Final Milestone in Carl Zeiss Agreement | May 4, 2020 | Other filings | ASX |
|---|
| OIL March 2020 Quarterly Report and Appendix 4C | Apr 30, 2020 | Quarterly report | ASX |
|---|
| Corporate Update | Mar 19, 2020 | Other filings | ASX |
|---|
| Appendix 4D and Financial Statements - 31 December 2019 | Feb 28, 2020 | Interim report | ASX |
|---|
| Corporate Update - January 2020 | Jan 30, 2020 | Other filings | ASX |
|---|
| Appointment of Second China Distributor | Dec 5, 2019 | Other filings | ASX |
|---|
| 2019 AGM Presentation | Nov 27, 2019 | Other filings | ASX |
|---|
| Optiscan Market Update | Nov 24, 2019 | Other filings | ASX |
|---|
| OIL initiates FDA feedback for Oral Cancer 510(k) submission | Nov 3, 2019 | Other filings | ASX |
|---|
| Appointment of new China Distributor | Oct 15, 2019 | Other filings | ASX |
|---|
| Leading Aus & US Hospital Collaboration to trial OIL device | Sep 23, 2019 | Other filings | ASX |
|---|
| Appendix 4E and 2019 Annual Report | Aug 30, 2019 | Annual report | ASX |
|---|
| Optiscan System Approved for Prestigious Cancer Centre Trial | Aug 21, 2019 | Other filings | ASX |
|---|
| Investor Presentation - June 2019 | Jun 14, 2019 | Other filings | ASX |
|---|
| Optiscan Secures Strong Support in $1.70 M Capital Raising | Jun 13, 2019 | Financing | ASX |
|---|
| OptiScan March 2019 Presentation | Mar 13, 2019 | Other filings | ASX |
|---|
| Appendix 4D and Financial Statements - 31 Dec 2018 | Feb 28, 2019 | Interim report | ASX |
|---|
| Collaboration Agreement with Summit Biomedical Imaging LLC | Feb 26, 2019 | Other filings | ASX |
|---|
| OptiScan technology used in research at major cancer centre | Feb 25, 2019 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation | Nov 6, 2018 | Trading halt or suspension | ASX |
|---|
| ZEISS achieves another milestone on regulatory pathway | Nov 6, 2018 | Other filings | ASX |
|---|
| Suspension from Official Quotation | Nov 1, 2018 | Trading halt or suspension | ASX |
|---|
| Clinical Trial - Assessment of Breast Cancer Margin | Oct 14, 2018 | Other filings | ASX |
|---|
| Appendix 4E and 2018 Annual Report | Aug 31, 2018 | Annual report | ASX |
|---|
| Market Update | Jun 13, 2018 | Other filings | ASX |
|---|
| ZEISS CONVIVO and Appointment of Interim Executive Chairman | May 31, 2018 | Management or board change | ASX |
|---|
| Appendix 4D and Financial Statements - 31 Dec 2017 | Feb 28, 2018 | Interim report | ASX |
|---|
| Update on CEO Recruitment and Interim Management | Feb 15, 2018 | Other filings | ASX |
|---|
| Market Update - Resignation of CEO | Jan 22, 2018 | Management or board change | ASX |
|---|
| ViewnVivo installed for evaluation at Stanford University | Nov 16, 2017 | Other filings | ASX |
|---|
| First Sales of ViewnVivo in the Chinese Market | Nov 12, 2017 | Other filings | ASX |
|---|
| Zeiss/Optiscan collaboration unveils Convivo | Oct 9, 2017 | Other filings | ASX |
|---|
| Share Purchase Plan and Placement Completion | Oct 3, 2017 | Financing | ASX |
|---|
| Carl Zeiss Meditec to unveil in vivo Digital Biopsy Tool | Sep 20, 2017 | Other filings | ASX |
|---|
| An update from the Chairman | Sep 12, 2017 | Other filings | ASX |
|---|
| Preliminary Final Report - Appendix 4E | Aug 29, 2017 | Results | ASX |
|---|
| Share Placement and Underwritten Share Purchase Plan | Aug 23, 2017 | Financing | ASX |
|---|
| ViewnVivo Update | Aug 16, 2017 | Other filings | ASX |
|---|
| Investor Presentation - July 2017 | Jul 3, 2017 | Other filings | ASX |
|---|
| Optiscan Appoints Exclusive North American Distributor | Jun 28, 2017 | Other filings | ASX |
|---|
| Amended Appendix 4D | Mar 8, 2017 | Interim report | ASX |
|---|
| Appendix 4D and Financial Statements - 31 Dec 2016 | Feb 28, 2017 | Interim report | ASX |
|---|
| Cleansing Prospectus | Dec 27, 2016 | Offer document | ASX |
|---|
| Prospectus - Share and Option Issues approved at AGM | Dec 21, 2016 | Offer document | ASX |
|---|
| Share Placement | Dec 20, 2016 | Financing | ASX |
|---|
| Pre-clinical research product launch | Nov 22, 2016 | Other filings | ASX |
|---|
| Receipt of R&D tax rebate incentive | Nov 8, 2016 | Other filings | ASX |
|---|
| Preliminary Final Report- Appendix 4E | Aug 31, 2016 | Results | ASX |
|---|
| Update on cooperation with Carl Zeiss Meditec | Aug 21, 2016 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation - 22 August 2016 | Aug 19, 2016 | Trading halt or suspension | ASX |
|---|
| Shares issued 19 August 2016 and request for reinstatement | Aug 19, 2016 | Other filings | ASX |
|---|
| NEW FUNDING FOR OPTISCAN | Mar 30, 2016 | Other filings | ASX |
|---|
| Zeiss Neurosurgery Purchase Order | Mar 30, 2016 | Other filings | ASX |
|---|
| Shareholder Update June 2012 | Mar 30, 2016 | Other filings | ASX |
|---|
| $2M Funding from Bergen Global Opportunity Fund, LP | Mar 30, 2016 | Other filings | ASX |
|---|
| Zeiss Milestones Actualised | Mar 30, 2016 | Other filings | ASX |
|---|
| Update, Capital Raise and Appendix 4E | Mar 30, 2016 | Results | ASX |
|---|
| Trading Halt Request | Mar 30, 2016 | Trading halt or suspension | ASX |
|---|
| New Funding Facility and Operations Update | Mar 30, 2016 | Operations update | ASX |
|---|
| Optiscan in Clinical Study at St Vincents Sydney | Mar 30, 2016 | Other filings | ASX |
|---|
| Optiscan Receives R&D Tax Incentive, Loan Repaid | Feb 11, 2016 | Other filings | ASX |
|---|
| Board Changes and Funding Update | Feb 10, 2016 | Other filings | ASX |
|---|
| CellLIVE Update | Feb 10, 2016 | Other filings | ASX |
|---|
| Optiscan Zeiss Collaboration Update | Feb 10, 2016 | Other filings | ASX |
|---|
| Global Launch of CellLIVe in Hawaii, USA | Feb 10, 2016 | Other filings | ASX |
|---|
| Optiscan Appendix 4E and Financial Statements | Feb 10, 2016 | Results | ASX |
|---|
| Board Changes at Optiscan | Feb 10, 2016 | Other filings | ASX |
|---|
| Non-Renounceable Issue | Feb 10, 2016 | Other filings | ASX |
|---|
| Funding and Update | Feb 10, 2016 | Other filings | ASX |
|---|
| Half Yearly Report and Accounts | Feb 10, 2016 | Interim report | ASX |
|---|
| Major Milestone Recognised | Feb 10, 2016 | Other filings | ASX |
|---|
| Major Step in Zeiss Product Development | Feb 10, 2016 | Other filings | ASX |
|---|
| New Global Supply Agreement | Feb 10, 2016 | Other filings | ASX |
|---|
| New US Patent for Optiscan | Feb 10, 2016 | Other filings | ASX |
|---|
| March Quarter 2010 Update | Feb 10, 2016 | Other filings | ASX |
|---|